JP2006500315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500315A5 JP2006500315A5 JP2003559504A JP2003559504A JP2006500315A5 JP 2006500315 A5 JP2006500315 A5 JP 2006500315A5 JP 2003559504 A JP2003559504 A JP 2003559504A JP 2003559504 A JP2003559504 A JP 2003559504A JP 2006500315 A5 JP2006500315 A5 JP 2006500315A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- hydrogen
- heterocyclic
- alkylcarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 8
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 7
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000004438 haloalkoxy group Chemical group 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- -1 complex Ring Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000003725 azepanyl group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- FXIPXWLVYIHFEP-OAQYLSRUSA-N 4-[4-[3-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]phenyl]benzonitrile Chemical compound C1[C@H](N(C)C)CCN1CCCOC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 FXIPXWLVYIHFEP-OAQYLSRUSA-N 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 1
- KFHYZKCRXNRKRC-MRXNPFEDSA-N abt-239 Chemical compound C[C@@H]1CCCN1CCC1=CC2=CC(C=3C=CC(=CC=3)C#N)=CC=C2O1 KFHYZKCRXNRKRC-MRXNPFEDSA-N 0.000 claims 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 claims 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 claims 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000011661 metabolic syndrome X Diseases 0.000 claims 1
- AVAWMINJNRAQFS-UHFFFAOYSA-N n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)C1CCNC1 AVAWMINJNRAQFS-UHFFFAOYSA-N 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical group O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 claims 1
- 0 *c(c(*)c1*)c(*)c(**C2(P)IN(*)*)c1C2=* Chemical compound *c(c(*)c1*)c(*)c(**C2(P)IN(*)*)c1C2=* 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/043,848 US20030134835A1 (en) | 2002-01-11 | 2002-01-11 | Histamine-3 receptor ligands for diabetes conditions |
| US10/326,546 US20030153548A1 (en) | 2002-01-11 | 2002-12-23 | Histamine-3 receptor ligands for diabetic conditions |
| PCT/US2003/000733 WO2003059342A1 (en) | 2002-01-11 | 2003-01-10 | Histamine-3 receptor ligands for diabetic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006500315A JP2006500315A (ja) | 2006-01-05 |
| JP2006500315A5 true JP2006500315A5 (enExample) | 2006-02-16 |
Family
ID=26720877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003559504A Pending JP2006500315A (ja) | 2002-01-11 | 2003-01-10 | 糖尿病状態に用いるヒスタミン−３受容体リガンド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050113435A1 (enExample) |
| EP (1) | EP1474132A1 (enExample) |
| JP (1) | JP2006500315A (enExample) |
| AU (1) | AU2003235687A1 (enExample) |
| CA (1) | CA2473232C (enExample) |
| MX (1) | MXPA04006777A (enExample) |
| PL (1) | PL373586A1 (enExample) |
| WO (1) | WO2003059342A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| WO2004024707A2 (en) * | 2002-09-16 | 2004-03-25 | Abbott Laboratories | Process for preparing amine type substituted benzofurans |
| US6822101B2 (en) | 2002-09-16 | 2004-11-23 | Abbott Laboratories | Process for preparing amine-substituted benzofurans |
| JP2007528860A (ja) * | 2003-07-28 | 2007-10-18 | 財団法人大阪産業振興機構 | 血糖降下用組成物 |
| US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| EP1717234A1 (en) * | 2005-04-29 | 2006-11-02 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| EP1717233A1 (en) * | 2005-04-29 | 2006-11-02 | Bioprojet | Histamine H3-receptor ligands and their therapeutic application |
| FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
| AR065495A1 (es) * | 2007-03-02 | 2009-06-10 | Schering Corp | Metodos para usar derivados de bencimidazol para tratar o prevenir dolor, diabetes, complicacion diabetica composiciones. |
| MX2009009417A (es) * | 2007-03-02 | 2009-09-11 | Schering Corp | Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor. |
| EP4251148A1 (en) | 2020-11-27 | 2023-10-04 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4096331A (en) * | 1976-12-28 | 1978-06-20 | A. H. Robins Company, Incorporated | 1-Substituted-3-aminoethoxypyrrolidines |
| GB2056441B (en) * | 1979-07-26 | 1983-07-06 | Kyowa Hakko Kogyo Kk | Derivatives of benzo(b)furan and pharmaceutical compositions containing them |
| US4447620A (en) * | 1982-06-08 | 1984-05-08 | The Upjohn Company | Imidazolyl-substituted benzothiophenes |
| US4452986A (en) * | 1982-06-08 | 1984-06-05 | The Upjohn Company | Imidazolyl-substituted benzofurans |
| NZ270418A (en) * | 1994-02-07 | 1997-09-22 | Eisai Co Ltd | Polycyclic triazole & imidazole derivatives, antifungal compositions |
| WO1998052946A1 (en) * | 1997-12-02 | 1998-11-26 | Dr. Reddy's Research Foundation | Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension |
| US6136559A (en) * | 1998-10-07 | 2000-10-24 | Ortho Pharmaceutical Corporation | DNA encoding as human histamine receptor of the H3 subtype |
| AU3957600A (en) * | 1999-04-26 | 2000-11-10 | Boehringer Ingelheim International Gmbh | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
| JP2003534245A (ja) * | 2000-03-17 | 2003-11-18 | ノボ ノルディスク アクティーゼルスカブ | ヒスタミンｈ３受容体リガンドとしての縮合環イミダゾール |
| US6437147B1 (en) * | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
| US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| US6316475B1 (en) * | 2000-11-17 | 2001-11-13 | Abbott Laboratories | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications |
| IL159320A0 (en) * | 2001-06-12 | 2004-06-01 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
| NZ534582A (en) * | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
-
2003
- 2003-01-10 MX MXPA04006777A patent/MXPA04006777A/es active IP Right Grant
- 2003-01-10 JP JP2003559504A patent/JP2006500315A/ja active Pending
- 2003-01-10 AU AU2003235687A patent/AU2003235687A1/en not_active Abandoned
- 2003-01-10 EP EP03729628A patent/EP1474132A1/en not_active Withdrawn
- 2003-01-10 WO PCT/US2003/000733 patent/WO2003059342A1/en not_active Ceased
- 2003-01-10 CA CA2473232A patent/CA2473232C/en not_active Expired - Fee Related
- 2003-01-10 PL PL03373586A patent/PL373586A1/xx not_active Application Discontinuation
-
2004
- 2004-10-06 US US10/959,799 patent/US20050113435A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006500315A5 (enExample) | ||
| JP2010527373A5 (enExample) | ||
| JP2014524934A5 (enExample) | ||
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| JP2011529029A5 (enExample) | ||
| JP2013500267A5 (enExample) | ||
| CA2613303A1 (en) | An oxime derivative for use as a glucokinase activator | |
| RU2006116887A (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида, способ получения указанных соединений и их применение в терапии | |
| TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
| JP2004520292A5 (enExample) | ||
| RU2006101452A (ru) | Пиридазинил-пиперазины и их применение в качестве лигандов h3 гистаминового рецептора | |
| JP2012501312A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2006507220A5 (enExample) | ||
| JP2010510233A5 (enExample) | ||
| JP2011507896A5 (enExample) | ||
| JP2009526831A5 (enExample) | ||
| CA2409741A1 (en) | Tnf-.alpha. production inhibitors | |
| JP2006506443A5 (enExample) | ||
| JP2009511519A5 (enExample) | ||
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| JP2007520440A5 (enExample) | ||
| CA2617817A1 (en) | Thiazole derivatives for treating or preventing sleep disorders | |
| JP2006511446A5 (enExample) |